Association of Hormone Therapy With Depression During Menopause

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, NOVEMBER 1, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.39491?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110122

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: The findings of this study of women in Denmark followed up from age 45 suggest that systemically administered (oral or transdermal) hormonal therapy before and during menopause is associated with higher risk of depression, especially in the years immediately after initiation, whereas locally administered (intravaginal or intrauterine) hormonal therapy is associated with lower risk of depression for women 54 years or older.

Authors: Merete Osler, M.D., Ph.D., D.M.Sc., of the Bispebjerg and Frederiksberg Hospitals in Frederiksberg, Denmark, is the corresponding author.

  

(doi:10.1001/jamanetworkopen.2022.39491)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.